Ionis Pharmaceuticals (IONS) Reports Pfizer (PFE) to Begin Phase 2b Clinical Study of Vupanorsen (AKCEA-ANGPTL3-LRx)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. SPY
4. ABBV
5. META
6. ACN
7. BLZE
8. IBM
9. NKE
10. MU

Go back to Ionis Pharmaceuticals (IONS) Reports Pfizer (PFE) to Begin Phase 2b Clinical Study of Vupanorsen (AKCEA-ANGPTL3-LRx)

Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)

November 3, 2020 6:00 PM EST

CARLSBAD, Calif. and BOSTON, Nov. 3, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary Akcea Therapeutics, Inc., today announced that Pfizer Inc. (NYSE: PFE) has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-LRx) in statin-treated patients with elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs). The study, Targeting ANGPTL3 with an antisense oligonucleotide in adults with dyslipidemia (TRANSLATE-TIMI 70), will evaluate various doses of vupanorsen to inform potential future development.

In the Phase... More